MARKET

GILD

GILD

Gilead Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

68.51
+0.70
+1.03%
After Hours: 68.30 -0.21 -0.31% 19:58 01/21 EST
OPEN
68.12
PREV CLOSE
67.81
HIGH
69.07
LOW
67.69
VOLUME
14.84M
TURNOVER
--
52 WEEK HIGH
74.12
52 WEEK LOW
61.39
MARKET CAP
85.94B
P/E (TTM)
11.73
1D
5D
1M
3M
1Y
5Y
FDA expands use of Gilead's COVID drug remdesivir to non-hospitalized patients
Gilead's (NASDAQ:GILD) COVID-19 treatment Veklury (remdesivir) can now be used in non-hospitalized adults and adolescents at high risk of progressing to severe disease. The FDA late Friday approved the company's
Seekingalpha · 1d ago
FDA expands use of remdesivir to patients with high risk of hospitalization
reuters.com · 1d ago
BRIEF-FDA Takes Actions To Expand Use Of Treatment For Outpatients With Mild-To-Moderate Covid-19
reuters.com · 1d ago
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
FOSTER CITY, Calif., January 21, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted expedited approval of a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the trea...
Business Wire · 1d ago
Corbenic Partners LLC Buys JPMorgan Ultra-Short Municipal Income ETF, WisdomTree Emerging ...
Investment company Corbenic Partners LLC (Current Portfolio) buys JPMorgan Ultra-Short Municipal Income ETF, WisdomTree Emerging Markets ex-State-Owned Enterpr, WisdomTree International Hedged Quality Dividend G, Salesforce.com Inc, Vanguard S&P 500 Growth...
GuruFocus.com · 2d ago
Gibraltar Capital Management, Inc. Buys Janus Henderson AAA CLO ETF, Coterra Energy Inc, Boeing ...
Tulsa, OK, based Investment company Gibraltar Capital Management, Inc. (Current Portfolio) buys Janus Henderson AAA CLO ETF, Coterra Energy Inc, Boeing Co, AAON Inc, Coca-Cola Co, sells PowerShares QQQ Trust Ser 1, General Dynamics Corp, Prudential Financi...
GuruFocus.com · 2d ago
Columbus Macro, LLC Buys SPDR Portfolio Short Term Corporate Bond ETF, PowerShares QQQ Trust ...
Investment company Columbus Macro, LLC (Current Portfolio) buys SPDR Portfolio Short Term Corporate Bond ETF, PowerShares QQQ Trust Ser 1, iShares Core U.S.
GuruFocus.com · 2d ago
Gilead Policy Papers Show Pandemic's Impact on HIV Prevention and Care
For nearly two years now, the COVID-19 pandemic has created an unprecedented challenge to public health and healthcare systems around the world. It has also had a ripple effect on HIV services, rai...
News Direct · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GILD. Analyze the recent business situations of Gilead Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 31 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

12.90%Strong Buy
29.03%Buy
54.84%Hold
3.23%Under-perform
0.00%Sell
Analyst Price Target
The average GILD stock price target is 77.08 with a high estimate of 100.00 and a low estimate of 63.00.
High100.00
Average77.08
Low63.00
Current 68.51
EPS
Actual
Estimate
0.661.331.992.65
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 2.21K
Institutional Holdings: 1.11B
% Owned: 88.26%
Shares Outstanding: 1.25B
TypeInstitutionsShares
Increased
601
48.54M
New
115
7.93M
Decreased
580
39.00M
Sold Out
83
2.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Chairman/Chief Executive Officer/Director
Daniel O'Day
Chief Financial Officer
Andrew Dickinson
Executive Vice President
Flavius Martin
Other
Johanna Mercier
Other
Merdad Parsey
Lead Director/Independent Director
Kevin Lofton
Independent Director
Jacqueline Barton
Independent Director
Jeffrey Bluestone
Independent Director
Sandra Horning
Independent Director
Kelly Kramer
Independent Director
Harish Manwani
Independent Director
Javier Rodriguez
Independent Director
Anthony Welters
Declaration Date
Dividend Per Share
Ex-Div Date
10/28/2021
Dividend USD 0.71
12/14/2021
07/29/2021
Dividend USD 0.71
09/14/2021
04/27/2021
Dividend USD 0.71
06/14/2021
02/04/2021
Dividend USD 0.71
03/12/2021
10/28/2020
Dividend USD 0.68
12/14/2020
07/30/2020
Dividend USD 0.68
09/14/2020
04/29/2020
Dividend USD 0.68
06/11/2020
02/03/2020
Dividend USD 0.68
03/12/2020
10/23/2019
Dividend USD 0.63
12/12/2019
07/29/2019
Dividend USD 0.63
09/12/2019
05/01/2019
Dividend USD 0.63
06/13/2019
02/01/2019
Dividend USD 0.63
03/14/2019
10/24/2018
Dividend USD 0.57
12/13/2018
07/24/2018
Dividend USD 0.57
09/13/2018
04/30/2018
Dividend USD 0.57
06/14/2018
02/05/2018
Dividend USD 0.57
03/15/2018
10/25/2017
Dividend USD 0.52
12/14/2017
07/25/2017
Dividend USD 0.52
09/14/2017
05/01/2017
Dividend USD 0.52
06/14/2017
02/06/2017
Dividend USD 0.52
03/14/2017
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Webull offers kinds of Gilead Sciences, Inc. stock information, including NASDAQ:GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.